Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Item

http://www.wikidata.org/entity/Q34104748

Q34104748

about

Comparison of echinocandin antifungals Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis In vitro activity of caspofungin against Candida albicans biofilms.Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.Overview of vertebrate animal models of fungal infection.Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis.New methods to assess susceptibilities of Aspergillus isolates to caspofungin.Caspofungin: first approved agent in a new class of antifungals.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans Phase II dose escalation study of caspofungin for invasive Aspergillosis.New and emerging antifungal agents: impact on respiratory infections.Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.Antifungal pharmacokinetics and pharmacodynamics Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Caspofungin: an overview.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The echinocandins.Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCR Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis The pharmacology and clinical use of caspofungin.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.

P2860

Q28273738-F2A9AB82-6FC3-4A30-B427-CFA54591D005 Q28727508-C6CDDA79-4A59-4813-9DD9-9337039F38CE Q31114513-15A08C01-17CD-4498-B2AC-E2C081020C8F Q33366929-06656BC1-7149-4B1C-981F-3CA86B51254E Q33689767-D1D3520E-4A60-4A1A-885D-602463F764A5 Q33757912-8D30B88B-D2C5-4E0B-B572-DF0FA38ADCC3 Q34123805-C0F2BB7F-6238-42D7-9A66-83CF826D42A8 Q34175500-28F65EA3-75B8-4717-B9D1-0968940CB9D0 Q34228214-6809FC89-1985-4363-9CE2-69CCB03C45CC Q34510443-D237F0D1-3088-409A-B9CC-AC84AB1C7989 Q34719835-5A74DC1B-37B8-43E6-B04A-75767C2732D9 Q34952419-3BEF2A0F-8373-434F-9076-954B8F5F4388 Q34956645-F36EE021-7DBC-47FF-8060-374B97F906B0 Q35124726-BA3AB61C-5E9B-408E-886A-C873F5157745 Q35185757-6AA25AF6-4156-4946-A660-DF08D4D7C37E Q35194409-A8C04DBA-2E0A-4C27-8016-0DA9C50AED49 Q35215384-BCA8AD23-941F-4B1A-99A9-6C5ADAA81985 Q35598439-C328260A-0597-457E-829F-939868CAABFD Q35627629-F6B50724-DEF7-4692-81AC-F9ED9F07F560 Q35647724-A8B3B491-73B2-4CF3-B984-81BEE93D6AC9 Q35663841-CDDF743F-A40B-4AB3-BA13-1508633D10D7 Q35666505-10310EFE-E591-4B70-8E0F-D244E5B3DE17 Q35666627-3C18819F-F5A1-42C4-A8D9-F9C395349A94 Q35745822-11C5FB6D-63D0-42DF-AD33-1BF592202FA7 Q35840760-7340D962-A498-4747-ADEF-E0E5E872056E Q36176371-A8723B4C-36F0-437E-A0FD-82717284B04E Q36278031-FEE927E3-D831-4EC9-97EA-863556F7C5FD Q36425025-D1B02293-7EC7-4BB3-8A93-45141CB41C88 Q36441524-69FC7ECD-0D41-4579-9731-20601BE880FF Q36626518-C508A452-70D7-4C31-A989-1E22A4F19708 Q36742397-F986BB35-B042-476D-BC8E-4F3E3B3EBD16 Q36744831-B0722F8E-E70A-45F9-8E30-495283A65954 Q36747468-82EF74C1-4641-4589-99DE-FEDE524E6569 Q36757591-82C18E2D-56A6-48D7-B8EE-DD5AF9FEB7C3 Q36788428-EDD20BCA-CF19-4C67-BBF9-8F390B83EF1C Q36932989-41C87AB1-866E-44E8-A0D4-D49FE7B4CF68 Q36948094-51A9EE82-B384-4B59-ACA2-61F6B87FAC01 Q36949553-A8A0FDF2-FF32-48B7-BBCC-386912BEDC75 Q36983268-E99F4001-FA01-49C6-9ACB-AF46F1590FFD Q37121115-E61E83AF-9CC1-4165-BF8F-10B36E9B496D

P2860

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Item

http://www.wikidata.org/entity/Q34104748

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue